Piper Sandler has established a target price of $110 for CRSP, suggesting significant upside potential from the current trading price of approximately $49.
The analysts attribute this optimistic projection to CRSP's strong product pipeline and favorable market conditions, which could enhance throughput and operational capacity.
This assessment reflects a strategic outlook on CRSP's ability to leverage its assets effectively within the biopharmaceutical sector.